Risdiplam 99.7%

Details:

Risdiplam (EVRY SDI, RG7916, RO 7034067) is an orally administered modifier of SmN2Pre-mRNA splitting that distributes to the central nervous system (CNS) and surrounding tissues.

Xuzhou Maikai Biotechnology Co., Ltd. was established in November 2021 with a registered capital of 15 million yuan. It is an emerging R&D enterprise based on anti-tumor drugs and biotechnology. The company cooperates with Dalian University of Technology, Zhejiang University, Jinan University, etc. Colleges and universities have good cooperative relations. The founders and shareholders of the company have 20 years of working experience in the chemical industry. They have in-depth understanding and control of the product market. The technology is mature and advanced, and the product quality has reached the pharmaceutical level, which has been fully recognized by customers in the industry.

The company focuses on the biochemical industry, aspires to become the world's leading brand in this industry, and contributes to the cause of human health. Since its establishment, the company has always adhered to and adhered to the core business philosophy of "morality-based, honesty-first", and regards providing value to customers as our responsibility, which has won praise from customers.

Business Distribution

Pharmaceutical Division

We are mainly responsible for the R&D, production and sales of pharmaceutical intermediates and APIs. The products are used in the fields of bio-buffering agents, anti-tumor drugs, cardiovascular and cerebrovascular diseases, steroid drugs, etc.

Electronic New Materials Division

We are mainly engaged in the research and development of additives for the battery industry, such as fluorinated ethylene carbonate (FEC), chlorinated ethylene carbonate (CEC), etc. We deliver high quality and high specification products to the battery industry at home and abroad.

Custom Synthesis Division

We mainly undertake the development of products commissioned by domestic and foreign pharmaceutical companies and CDMO companies. The company has strong technical research on special types of reactions such as coupling, chlorination, diazotization, hydrogenation, and ammoniation. We are also currently working on product process improvement using continuous flow equipment to obtain faster and safer reaction conditions.

Pesticide Division

We are mainly responsible for the research and development, production and sales of intermediates and original drugs for plant growth regulator products.